$LIMN

Liminatus Pharma, Inc.

Liminatus Pharma is a pre-clinical biopharmaceutical company developing cancer therapies that use the immune system to target cancer cells. Its single product candidate, IBA101, is a humanized anti-CD47 monoclonal antibody designed to block an immune checkpoint. The company is initially developing it for advanced solid cancers, including non-small cell lung cancer, and is preparing for a Phase 1 clinical trial. Liminatus reports that the antibody preferentially binds to immune cells rather than red blood cells and platelets. It also describes research into possible applications in chronic inflammation and obesity. Liminatus holds an exclusive worldwide license to develop and commercialize its CD47 product and related companion diagnostics. It relies on third-party manufacturers for drug substance and finished products, and its license makes it responsible for development costs. The company is headquartered in Cerritos, California.

0
1
0

No SEC Form 4 filings for $LIMN in the last 30 days.

See all $LIMN insider activity →
Low

Liminatus Pharma, Inc. appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 16, 2026, Liminatus Pharma, Inc. (the “Company”) appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately. In this role, Mr. Kang will report to Chris Kim, the Company’s Chief Executive Officer, and will a

Liminatus Pharma, Inc. (LIMN): Entry into a Material Definitive Agreement

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with a non-U.S. investor, pursuant to which such investor agreed to subscribe for, and the Compan

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid pric

LIMN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning LIMN (Liminatus Pharma, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent LIMN coverage spans corporate actions, mergers & acquisitions and financial news.

What's driving LIMN

  • The hire signals a renewed focus on financing and capital markets initiatives, which can affect near-term funding expectations and risk appetite.

    SEC EDGAR 8-K · Nov 18, 2026

  • The modest capital raise will likely cause slight dilution and modest downward pressure on the stock.

    SEC EDGAR 8-K · Nov 3, 2026

  • Compliance regain removes delisting risk and may support price stability.

    SEC EDGAR 8-K · Sep 29, 2026

  • The split reduces float and may trigger short covering, but ongoing delisting risk adds downside pressure.

    ocbj.com · Sep 14, 2026

  • The new collaboration may accelerate clinical development in South Korea but the immediate market reaction was negative, suggesting short‑term sell pressure.

    ocbj.com · Aug 24, 2026

AlphAI scores every news story that mentions LIMN with an AI model for sentiment and relevance, and aggregates insider trades from Liminatus Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LIMN

Score
$LIMNLowExec change· appointed

Liminatus Pharma, Inc. appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 16, 2026, Liminatus Pharma, Inc. (the “Company”) appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately. In this role, Mr. Kang will report to Chris Kim, the Company’s Chief Executive Officer, and will a

$LIMNLowOffering· $650K · priced

Liminatus Pharma, Inc. (LIMN): Entry into a Material Definitive Agreement

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with a non-U.S. investor, pursuant to which such investor agreed to subscribe for, and the Compan

$LIMNLowListing notice· regained compliance

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid pric

Liminatus Expands Cancer Pipeline Amid Nasdaq Issues

Liminatus Pharma Inc. (LIMN) engaged Synex Consulting to advance its cancer therapy IBC101, acquired through a $320M deal. The therapy received South Korea's approval for a Phase 1/2a study. Liminatus faces Nasdaq listing challenges, recently transferred to the Nasdaq Capital Market, and completed a 1-for-50 reverse stock split. Shares fell 29% since the split.

Liminatus Partners with Korean Firm for CAR

Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.

Liminatus Pharma Inc.: Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Liminatus Pharma (Nasdaq: LIMN) said its shares transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective Aug. 4, 2026, keeping the ticker LIMN. Nasdaq’s Hearings Panel granted an extension to regain compliance with the minimum bid price rule, with a deadline of Sept. 3, 2026.

$LIMNMedShareholder vote

Liminatus Pharma, Inc. (LIMN): Submission of Matters to a Vote of Security Holders

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 3, 2026, Liminatus Pharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The holders of 32,446,373 shares of common stock, or approximately 48.31% of the outstandi

$LIMNMedM&A· acquirer · completed

Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha

Related tickers